A Study of Glucosylceramide Synthase and Glycolytic Pathway Enzymes in Patients with Hypereosinophilia
Open Access
- 31 March 2017
- journal article
- Published by Peertechz Publications Private Limited in International Journal of Immunotherapy and Cancer Research
- Vol. 3 (1), 015-018
- https://doi.org/10.17352/2455-8591.000014
Abstract
Glucosylceramide synthase is the rate limiting enzyme in ceramide glycosylation and shifts the balance between ceramide and glycosphingolipids towards proliferation and survival of cancer cells.Keywords
This publication has 16 references indexed in Scilit:
- Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular ProliferationDiagnostics, 2013
- B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramidesBlood, 2012
- Metabolism of short-chain ceramide by human cancer cells—Implications for therapeutic approachesBiochemical Pharmacology, 2010
- Chronic Eosinophilic Leukemias and the Myeloproliferative Variant of the Hypereosinophilic SyndromeImmunology and Allergy Clinics of North America, 2007
- WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemiaLeukemia, 2007
- cIAP‐2 and survivin contribute to cytokine‐mediated delayed eosinophil apoptosisEuropean Journal of Immunology, 2006
- Eosinophilia: secondary, clonal and idiopathicBritish Journal of Haematology, 2006
- Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosisAmerican Journal of Hematology, 2004
- Biologically active sphingolipids in cancer pathogenesis and treatmentNature Reviews Cancer, 2004
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeThe New England Journal of Medicine, 2003